BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30202920)

  • 1. Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
    Foolad F; Aitken SL; Shigle TL; Prayag A; Ghantoji S; Ariza-Heredia E; Chemaly RF
    Clin Infect Dis; 2019 May; 68(10):1641-1649. PubMed ID: 30202920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients.
    Gueller S; Duenzinger U; Wolf T; Ajib S; Mousset S; Berger A; Martin H; Serve H; Bug G
    Transpl Infect Dis; 2013 Aug; 15(4):435-40. PubMed ID: 23692664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes.
    Akhmedov M; Wais V; Sala E; Neagoie A; Nguyen TM; Gantner A; von Harsdorf S; Kuchenbauer F; Schubert A; Michel D; Döhner H; Bunjes D
    Transpl Infect Dis; 2020 Aug; 22(4):e13276. PubMed ID: 32162389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature.
    Trang TP; Whalen M; Hilts-Horeczko A; Doernberg SB; Liu C
    Transpl Infect Dis; 2018 Apr; 20(2):e12844. PubMed ID: 29360277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients.
    Permpalung N; Thaniyavarn T; Saullo JL; Arif S; Miller RA; Reynolds JM; Alexander BD
    Transplantation; 2020 Jun; 104(6):1280-1286. PubMed ID: 31568275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.
    Seo S; Campbell AP; Xie H; Chien JW; Leisenring WM; Englund JA; Boeckh M
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):589-96. PubMed ID: 23298855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.
    Shah DP; Ghantoji SS; Shah JN; El Taoum KK; Jiang Y; Popat U; Hosing C; Rondon G; Tarrand JJ; Champlin RE; Chemaly RF
    J Antimicrob Chemother; 2013 Aug; 68(8):1872-80. PubMed ID: 23572228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.
    Beaird OE; Freifeld A; Ison MG; Lawrence SJ; Theodoropoulos N; Clark NM; Razonable RR; Alangaden G; Miller R; Smith J; Young JA; Hawkinson D; Pursell K; Kaul DR
    Transpl Infect Dis; 2016 Apr; 18(2):210-5. PubMed ID: 26923867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections.
    Shah DP; Ghantoji SS; Ariza-Heredia EJ; Shah JN; El Taoum KK; Shah PK; Nesher L; Hosing C; Rondon G; Champlin RE; Chemaly RF
    Blood; 2014 May; 123(21):3263-8. PubMed ID: 24700783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients.
    Gorcea CM; Tholouli E; Turner A; Saif M; Davies E; Battersby E; Dignan FL
    J Hosp Infect; 2017 Feb; 95(2):214-217. PubMed ID: 28077243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients.
    Whimbey E; Champlin RE; Englund JA; Mirza NQ; Piedra PA; Goodrich JM; Przepiorka D; Luna MA; Morice RC; Neumann JL
    Bone Marrow Transplant; 1995 Sep; 16(3):393-9. PubMed ID: 8535312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.
    Boeckh M; Englund J; Li Y; Miller C; Cross A; Fernandez H; Kuypers J; Kim H; Gnann J; Whitley R;
    Clin Infect Dis; 2007 Jan; 44(2):245-9. PubMed ID: 17173225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes.
    Waghmare A; Campbell AP; Xie H; Seo S; Kuypers J; Leisenring W; Jerome KR; Englund JA; Boeckh M
    Clin Infect Dis; 2013 Dec; 57(12):1731-41. PubMed ID: 24065324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.
    Li L; Avery R; Budev M; Mossad S; Danziger-Isakov L
    J Heart Lung Transplant; 2012 Aug; 31(8):839-44. PubMed ID: 22621746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies.
    Vakil E; Sheshadri A; Faiz SA; Shah DP; Zhu Y; Li L; Kmeid J; Azzi J; Balagani A; Bashoura L; Ariza-Heredia E; Chemaly RF
    Transpl Infect Dis; 2018 Dec; 20(6):e12994. PubMed ID: 30195271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation.
    Balassa K; Salisbury R; Watson E; Lubowiecki M; Tseu B; Maouche N; Jeffery K; Misbah SA; Benamore R; Rowley L; Barton D; Pawson R; Danby R; Rocha V; Peniket A
    J Infect; 2019 Jun; 78(6):461-467. PubMed ID: 30965067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation.
    Casey J; Morris K; Narayana M; Nakagaki M; Kennedy GA
    Bone Marrow Transplant; 2013 Nov; 48(12):1558-61. PubMed ID: 23912665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus infections in children with cancer.
    Chemaly RF; Ghantoji SS; Shah DP; Shah JN; El Taoum KK; Champlin RE; Nunez CA; Mulanovich V; Ariza-Heredia E
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e376-81. PubMed ID: 24327130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection.
    Chemaly RF; Torres HA; Munsell MF; Shah DP; Rathod DB; Bodey GP; Hosing C; Saifan C; Raad II; Champlin RE
    J Infect Dis; 2012 Nov; 206(9):1367-71. PubMed ID: 22927454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients.
    Marcelin JR; Wilson JW; Razonable RR;
    Transpl Infect Dis; 2014 Apr; 16(2):242-50. PubMed ID: 24621016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.